Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 19.11.2019 Börsentäglich über 12.000 News von 617 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JKVH ISIN: IE00B56GVS15 Ticker-Symbol: 8AK 
Tradegate
18.11.19
17:50 Uhr
18,300 Euro
-0,700
-3,68 %
1-Jahres-Chart
ALKERMES PLC Chart 1 Jahr
5-Tage-Chart
ALKERMES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
17,900
18,600
13:37
17,900
18,600
13:37

Aktuelle News zur ALKERMES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:01Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder105DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
► Artikel lesen
12:31Alkermes boosts CNS presence with $950m Rodin acquisition-
ALKERMES Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
09:42Alkermes to buy Rodin Therapeutics for up to $950m-
MoAlkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin1
MoStruggling Alkermes spends $950M sculpting Rodin buyout-
MoAlkermes forges $950M biotech buyout deal in a bold bet on an early-stage CNS drug platform1
MoAlkermes acquires Rodin Therapeutics for up to $950M2
MoAlkermes to acquire Rodin Therapeutics for up to $950 million2
MoAlkermes To Acquire Rodin Therapeutics95DUBLIN (dpa-AFX) - Biopharmaceutical company Alkermes plc (ALKS) and Rodin Therapeutics, Inc. announced that Alkermes will acquire privately-held biopharmaceutical company Rodin, which is...
► Artikel lesen
MoAlkermes plc. - 8-K, Current Report-
MoAlkermes to Acquire Rodin Therapeutics108- Acquisition to Expand Alkermes' Presence in CNS to a Wide Range of Neurodegenerative Diseases Through Epigenetic Control of Synaptogenesis - DUBLIN and BOSTON, Nov. 18, 2019 /PRNewswire/...
► Artikel lesen
12.11.Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences249DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday...
► Artikel lesen
12.11.Alkermes Receives $150M Biogen Milestone8
12.11.Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY1.615DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration...
► Artikel lesen
08.11.Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting263? Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab - ? Posters...
► Artikel lesen
07.11.Biotech Stock On The Radar: Alkermes At A Crossroads2
04.11.Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting755- Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 - DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it...
► Artikel lesen
30.10.Biogen, Alkermes win FDA approval of Tecfidera successor - but can they actually sell it?7
30.10.Alkermes Says FDA Approves Vumerity For Multiple Sclerosis205WASHINGTON (dpa-AFX) - Biogen Inc. (BIIB) and Alkermes plc (ALKS) said that the U.S. Food and Drug Administration approved Vumerity for the treatment of relapsing forms of multiple sclerosis...
► Artikel lesen
30.10.UPDATE 1-FDA approves Biogen and Alkermes' multiple sclerosis drug6
Seite:  Weiter >>
100 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1